![Computational Analysis of Kinase Inhibitors Identifies Promiscuity Cliffs across the Human Kinome | ACS Omega Computational Analysis of Kinase Inhibitors Identifies Promiscuity Cliffs across the Human Kinome | ACS Omega](https://pubs.acs.org/cms/10.1021/acsomega.8b02998/asset/images/medium/ao-2018-02998b_0009.gif)
Computational Analysis of Kinase Inhibitors Identifies Promiscuity Cliffs across the Human Kinome | ACS Omega
![Biomedicines | Free Full-Text | Sorafenib versus Lenvatinib Causes Stronger Oxidative Damage to Membrane Lipids in Noncancerous Tissues of the Thyroid, Liver, and Kidney: Effective Protection by Melatonin and Indole-3-Propionic Acid Biomedicines | Free Full-Text | Sorafenib versus Lenvatinib Causes Stronger Oxidative Damage to Membrane Lipids in Noncancerous Tissues of the Thyroid, Liver, and Kidney: Effective Protection by Melatonin and Indole-3-Propionic Acid](https://www.mdpi.com/biomedicines/biomedicines-10-02890/article_deploy/html/images/biomedicines-10-02890-g001.png)
Biomedicines | Free Full-Text | Sorafenib versus Lenvatinib Causes Stronger Oxidative Damage to Membrane Lipids in Noncancerous Tissues of the Thyroid, Liver, and Kidney: Effective Protection by Melatonin and Indole-3-Propionic Acid
![Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK) | Journal of Medicinal Chemistry Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK) | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/jm2007613/asset/images/large/jm-2011-007613_0019.jpeg)